ALS Compendium

Title: The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

Year Published: 2011

Observation: Trial for dexapramipexole. Attenuation of 20.5% in rate of decline of ALSFRS-R scores for the 300mn group relative to the 50mg group. 68% reduction in hazard of mortality for 300mg group relative to 50mg group

Comment: Dexpramipexole was safe and well tolerated

Citation: Cudkowicz, M., Bozik, M. E., Ingersoll, E. W., Miller, R., Mitsumoto, H., Shefner, J., … Gribkoff, V. K. (2011). The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine, 17(12), 1652–6. doi:10.1038/nm.2579

Back to Homepage